Mission Pharmacal Company and DARA BioSciences Inc. have expanded their partnership with the U.S. launch of Oravig (miconazole), the first and only orally- dissolving muco-adhesive buccal tablet approved to treat adults with oral thrush. In total, more than 28 million prescriptions are currently filled annually for oral thrush in the U.S. Specific to the Oravig launch, the Mission sales team will focus on reaching primary care physicians while the DARA sales force focuses on the oncology mark...